Intellia Therapeutics, INC. (NTLA) — 10-Q Filings

10-Q Filings (5)

• Intellia Narrows Losses, Boosts Revenue on R&D Cuts — Nov 6, 2025 Risk: high
  Intellia Therapeutics, Inc. (NTLA) reported a net loss of $101.3 million for the three months ended September 30, 2025, an improvement from the $135.7 million n
• Intellia's Q2 Loss Widens on Soaring R&D, Revenue Dips 24% — Aug 7, 2025 Risk: high
  Intellia Therapeutics reported a net loss of $120.3 million for the second quarter of 2025, a significant increase from the $105.1 million net loss in the same
• Intellia Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Intellia Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 40 Erie Street, Suite 130, Cambridge, MA, reported on i
• Intellia Therapeutics Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Intellia Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and business operations. Key fin
• Intellia Therapeutics Reports First Quarter 2024 Financial Results — May 9, 2024 Risk: medium
  Intellia Therapeutics, Inc. (NTLA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Intellia Therapeutics, Inc. filed a 10-Q for the period ending M

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX